Research Article
Predictors of Effectiveness of Glucagon-Like Peptide-1 Receptor Agonist Therapy in Patients with Type 2 Diabetes and Obesity
Table 2
Characteristics of the participants at baseline.
| | Characteristics | Patients on the aGLP-1, | Reference range |
| | Age (years) | 27-75 (57.1) | NA | | Diabetes duration (years) | | NA | | Body mass (kg) | | NA | | BMI (kg/m2) | | <25 | | WC (cm) | | | | Men | 125.0 (116.0; 148.0) | <90 | | Women | 116.0 (104.8; 132.5) | <84 | | НbA1c (%) | | <6.5 | | Glucose fasting (mmol/l) | | 3.3-6.1 | | C-peptide fasting (ng/ml) | | 0.78-5.19 | | C-peptide after test (ng/ml) | | >9.9 (↑ on >50% from baseline) | | НОМА-IR | | <2.77 | | НОМА-β (%) | 35.7 (24.5; 61.0) | ≥100 | | TC (mmol/l) | | <4.5 | | HDL (mmol/l) | | | | Men | 1.01 (0.79; 1.13) | >1.0 | | Women | 1.07 (0.8; 1.3) | >1.2 | | LDL (mmol/l) | | <1.8 | | TG (mmol/l) | 1.9 (1.5; 3.2) | <1.7 | | SBP (mm Hg) | | <140 | | DBP (mm Hg) | | <85 |
|
|
Min-max (mean age). 2 hours after breakfast in the meal tolerance test. |
